Kineta ROA 2014-2024 | KANT
Current and historical return on assets (ROA) values for Kineta (KANT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Kineta ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-06-30 |
$-0.02B |
$0.00B |
-350.00% |
| 2024-03-31 |
$-0.02B |
$0.00B |
-175.61% |
| 2023-12-31 |
$-0.01B |
$0.01B |
-107.69% |
| 2023-09-30 |
$-0.06B |
$0.01B |
-393.22% |
| 2023-06-30 |
$-0.06B |
$0.02B |
-406.90% |
| 2023-03-31 |
$-0.07B |
$0.01B |
-472.73% |
| 2022-12-31 |
$-0.06B |
$0.02B |
-345.95% |
| 2022-09-30 |
$0.00B |
$0.01B |
0.00% |
| 2022-06-30 |
$-0.00B |
$0.02B |
-12.31% |
| 2022-03-31 |
$-0.01B |
$0.03B |
-16.33% |
| 2021-12-31 |
$-0.01B |
$0.01B |
-18.75% |
| 2021-09-30 |
$-0.07B |
$0.07B |
-73.74% |
| 2021-06-30 |
$-0.06B |
$0.08B |
-72.51% |
| 2021-03-31 |
$-0.05B |
$0.09B |
-64.00% |
| 2020-12-31 |
$-0.05B |
$0.12B |
-65.36% |
| 2020-09-30 |
$0.00B |
$0.05B |
5.74% |
| 2020-06-30 |
$-0.00B |
$0.06B |
-6.43% |
| 2020-03-31 |
$-0.02B |
$0.07B |
-32.99% |
| 2019-12-31 |
$-0.03B |
$0.02B |
-36.36% |
| 2019-09-30 |
$-0.06B |
$0.09B |
-55.77% |
| 2019-06-30 |
$-0.07B |
$0.11B |
-64.34% |
| 2019-03-31 |
$-0.06B |
$0.12B |
-63.68% |
| 2018-12-31 |
$-0.06B |
$0.14B |
-67.59% |
| 2018-09-30 |
$-0.06B |
$0.06B |
-75.00% |
| 2018-06-30 |
$-0.05B |
$0.08B |
-70.43% |
| 2018-03-31 |
$-0.06B |
$0.08B |
-77.46% |
| 2017-12-31 |
$-0.06B |
$0.08B |
-85.20% |
| 2017-09-30 |
$-0.06B |
$0.06B |
-76.12% |
| 2017-06-30 |
$-0.05B |
$0.06B |
-62.65% |
| 2017-03-31 |
$-0.04B |
$0.08B |
-55.87% |
| 2016-12-31 |
$-0.04B |
$0.09B |
-52.05% |
| 2016-09-30 |
$-0.04B |
$0.10B |
-63.64% |
| 2016-06-30 |
$-0.03B |
$0.05B |
-113.79% |
| 2016-03-31 |
$-0.02B |
$0.05B |
-135.21% |
| 2015-12-31 |
$-0.02B |
$0.02B |
-484.21% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
